Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients with SARS-CoV-2 virus infection and with mild-to-moderate symptoms.
Description: Adverse Events (AEs)
Measure: Frequency of treatment-emergent adverse events (TEAEs) Time: 0 hours up to 41 daysDescription: Adverse Events
Measure: Number of participants who withdraw due to treatment-emergent adverse events (TEAEs) Time: 0 hours up to 41 daysDescription: Adverse Events
Measure: Frequency of treatment-emergent adverse events (TEAEs), causally related to study intervention Time: 0 hours up to 41 daysDescription: Serious Adverse Events
Measure: Frequency of treatment-emergent serious adverse events Time: 0 hours up to 41 daysDescription: Adverse Events
Measure: Frequency of treatment-emergent infusion site reactions Time: 0 hours up to 41 daysDescription: Percent change in laboratory parameters
Measure: Magnitude of abnormal hematologic laboratory findings Time: 0 hours up to 41 daysDescription: Adverse Events
Measure: Frequency of abnormal chemistry values Time: 0 hours up to 41 daysDescription: Adverse Events
Measure: Frequency of abnormal hematologic laboratory findings Time: 0 hours up to 41 daysDescription: Percent change in urinalysis parameters
Measure: Magnitude of abnormal urinalysis findings Time: 0 hours up to 41 daysDescription: ECG parameters
Measure: Change from baseline in PR values Time: 0 hours up to 41 daysDescription: ECG parameters
Measure: Change from baseline in RR values Time: 0 hours up to 41 daysDescription: ECG parameters
Measure: Change from baseline in QTc values Time: 0 hours up to 41 daysDescription: ECG parameters
Measure: Change from baseline in QTcF values Time: 0 hours up to 41 daysDescription: ECG parameters
Measure: Change from baseline in QRS values Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in pulse rate measurements Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in temperature values Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in respiratory rate values Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in systolic blood pressure Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in diastolic blood pressure Time: 0 hours up to 41 daysDescription: Vital sign measurements
Measure: Change from baseline in pulse oximetry/SpO2 measurement Time: 0 hours up to 41 daysDescription: plasma PK parameters
Measure: Change in concentration at 24 hours (C24[end of infusion]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in concentration, dose normalised, at 24 hours (C24 (dn) [end of infusion]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in concentration at 120 hours (C120[end of infusion]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in maximum observed concentration (Cmax) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in maximum observed concentration, dose normalised (Cmax [dn]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in concentration at steady state (Css) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in concentration at steady state, dose normalised (Css [dn]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in terminal half life (t1/2) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in clearance (CL) of PF-07304814 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity (AUCinf) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in area-under-the-curve plasma concentration from 0 to last quantifiable concentration (AUClast) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity, dose normalised (AUCinf [dn]) of PF-07304814 and PF-00835231 Time: 0 to 32 hoursDescription: plasma PK parameters
Measure: Change in steady state volume of distribution (Vss) of PF-00835231 Time: 0 to 32 hoursDescription: urinary PK parameters (Cohort 2 only)
Measure: Cumulative amount of unchanged drug excreted into urine (Ae) Time: 0 to 36 hoursDescription: urinary PK parameters (Cohort 2 only)
Measure: Percent of dose excreted as unchanged drug (Ae%) over dosing period Time: 0 to 36 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports